List of Otiprio drug patents

Otiprio is owned by Alk Abello.

Otiprio contains Ciprofloxacin.

Otiprio has a total of 8 drug patents out of which 0 drug patents have expired.

Otiprio was authorised for market use on 10 December, 2015.

Otiprio is available in injectable, suspension;otic dosage forms.

Otiprio can be used as treatment of otic infection or inflammation, the treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus, treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement.

The generics of Otiprio are possible to be released after 27 November, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9603796 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Apr, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205048 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Apr, 2029

(6 years from now)

US11369566 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Apr, 2029

(6 years from now)

US9233068 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders
Dec, 2029

(6 years from now)

US8318817 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Apr, 2030

(7 years from now)

US9220796 ALK ABELLO Sterilization of ciprofloxacin composition
Jul, 2035

(12 years from now)

US11040004 ALK ABELLO Otic gel formulations for treating otitis externa
Nov, 2037

(14 years from now)

US11246863 ALK ABELLO Ciprofloxacin otic composition and kits and method for using same
Nov, 2038

(15 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement; Treatment of otic infection or inflammation; The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in